The estimated Net Worth of Hugh M. O'neill is at least $4.43 Million dollars as of 14 November 2017. Mr. neill owns over 9,000 units of Mallinckrodt Plc stock worth over $13,701 and over the last 11 years he sold MNK stock worth over $0. In addition, he makes $4,412,780 as Executive Vice President and Chief Commercial Officer at Mallinckrodt Plc.
Hugh has made over 5 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of MNK stock worth $196,200 on 14 November 2017.
The largest trade he's ever made was buying 9,000 units of Mallinckrodt Plc stock on 14 November 2017 worth over $196,200. On average, Hugh trades about 680 units every 41 days since 2014. As of 14 November 2017 he still owns at least 40,297 units of Mallinckrodt Plc stock.
You can see the complete history of Mr. neill stock trades at the bottom of the page.
Hugh O'Neill is Executive Vice President, Chief Commercial Officer of the Company. He has executive responsibility for the Company's Specialty Brands products, directly managing all commercialization efforts and broad market access activities, as well as new product launch execution for assets in Mallinckrodt's near-term development portfolio. From April 2015 to May 2018, Mr. O'Neill served as our Executive Vice President and President, Autoimmune and Rare Diseases, and from September 2013 to April 2015, he served as Senior Vice President and President, U.S. Specialty Pharmaceuticals. Prior to joining Mallinckrodt in September 2013, Mr. O'Neill worked at Sanofi-Aventis for ten years where he held various commercial leadership positions including Vice President of Commercial Excellence from June 2012 to July 2013; General Manager, President of Sanofi-Aventis Canada from June 2009 to May 2012; and Vice President Market Access and Business Development from 2006 to 2009. Mr. O'Neill joined Sanofi in 2003 as its Vice President, United States Managed Markets. Mr. O'Neill previously served in a variety of positions of increasing responsibility for Sandoz Pharmaceuticals, Forest Laboratories, Novartis Pharmaceuticals and Pfizer Inc
As the Executive Vice President and Chief Commercial Officer of Mallinckrodt Plc, the total compensation of Hugh Neill at Mallinckrodt Plc is $4,412,780. There are 2 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
Hugh Neill is 56, he's been the Executive Vice President and Chief Commercial Officer of Mallinckrodt Plc since 2018. There are 10 older and 2 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
Hugh's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P...., and Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: